Leading Insulin Pump Manufacturers and their Approved Products
.png)
Published: September 2024
Insulin pumps have become increasingly sophisticated, incorporating features such as continuous glucose monitoring integration and smartphone connectivity to enhance diabetes management. We analyzed more than 25 companies that are actively engaged in manufacturing over 40 insulin pumps. In this article, discover the top 5 insulin pump manufacturers.
Over the past three to four decades, the prevalence of diabetes has quadrupled globally. Presently, this condition affects more than half a billion individuals across the world. This surge has intensified the need for highly efficient insulin delivery systems in order to support patients in managing their disease effectively. Conventional approaches (such as oral medicines and multiple daily injections) can be burdensome and prone to user error. As a result, there has been a rising adoption of insulin pumps, that offer more accurate and convenient insulin delivery (basal or bolus doses). Insulin pumps are small medical devices that deliver insulin continuously through the subcutaneous route, enabling better glycemic control and enhanced quality of life. Notably, the insulin pumps deliver different types of insulin, including ultra short-acting, short-acting, intermediate-acting, long-acting, ultra long-acting, and mixed preparations.
The ongoing advancements in technology have transformed the insulin pumps domain by improving their user-friendliness and the standard of care offered. These pumps are gaining traction and are becoming a primary treatment option for individuals with insulin-dependent diabetes. It is worth mentioning that the insulin pumps market is anticipated to witness steady growth in the coming years, owing to the rising cases of diabetes, integration of devices with artificial intelligence, clinical evidence (demonstrating advantages of insulin pump therapy over conventional methods) and increasing awareness among patients, caretakers and healthcare professionals.
Roots Analysis has conducted an exhaustive study on Insulin Pumps Market featuring the current market landscape of insulin pump manufacturers and future opportunity associated with the insulin pumps market, over the forecast period 2024-2035.
Table of Contents
Below, we have listed (in decreasing order of number of products), the top 5 insulin pump manufacturers:
- Medtronic
- SOOIL Development
- Roche
- Insulet Corporation
- Tandem Diabetic Care
Interested in exploring all 25+ insulin pump manufacturers across various regions?
In this Article, Discover the Details on Top 5 Insulin Pump Manufacturers
This article highlights the top 5 players to watch out for in this industry. These companies were chosen based on the number of insulin pumps being manufactured by them (having more than one insulin pump in their product portfolio and sufficient recent activity in the domain). It is essential to note that the selection of top players can differ substantially according to the defined criteria.
Leveraging Its Innovative Insulin Pump Technology, Medtronic’s Diabetes Segment is Returning to Growth in the US; Intent to Stay as Market Leader
 |
Medtronic specializes in developing innovative medical technologies, therapeutics and equipment addressing over 70 health issues. The product portfolio of the company encompasses different medical devices, such as cardiac devices, insulin pumps, patient monitoring systems and advanced surgical systems. Notably, the company has expanded its operations to 150 countries and is presently overseeing more than 300 clinical trials across the world. According to the company website, it has filed more than 46,000 patents for diverse products.
In Q1 FY25, Medtronic reported revenues of $647 million for its diabetes segment, an 11.8% increase from Q1 FY24. According to the company, the growth was mainly driven by continued adoption of the MiniMed 780G insulin pump system in the US. This sensor augmented insulin pump uses Guardian 4 sensor and was approved in the US in April 2023.
Insulin Pumps Portfolio:
The table below presents information on insulin pumps manufactured by Medtronic, providing details on the stage of development, type of pump (tubed or tubeless), degree of automation, and type of dose administered (basal or bolus).
 |
Recent Developments:
- August 2024: Medtronic entered into an OEM agreement with Abbott, under which the latter will develop CGM for Medtronic for use with their insulin pumps as well as pen systems.
- June 2024: Medtronic showcases the advantages of the MiniMed™ 780G system in American Diabetes Association's (ADA) 84th Scientific Sessions.
- June 2024: The company participated in 45th annual Goldman Sachs global healthcare conference, held in Dublin, Ireland.
- May 2024: The company entered into a product / technology integration agreement with Arecor to develop implantable insulin pumps.
- April 2024: The company participated in Genius Summit 2024, held in Dublin, Ireland.
- January 2024: The company participated in 42nd annual J.P. Morgan healthcare conference, held in Dublin, Ireland.
- June 2023: The company participated in 44th annual Goldman Sachs global healthcare conference, held in Dublin, Ireland.
Further information related to the insulin pump portfolio of Medtronic and other insulin pump manufacturers is available in the full report.
SOOIL Development, A South Korea Based Insulin Pump Manufacturer, Lacks CGM Technology for Development of an Automated Insulin Device
 |
SOOIL Development is engaged in the development and manufacturing of medical devices, with primary emphasis on diabetes care. In 1995, the company achieved a significant milestone when Korea's Ministry of Health and Welfare chose it for the Advanced Medical Technique Development Plan (G-7 Project); this initiative aimed to support Korean medical device companies with unique and innovative technological capabilities. Through this program, SOOIL Development became the first company (in this program) to commercially release an insulin pump, namely Dana Diabecare in 1998. Notably, the firm has established branches in every region of Korea as well as in more than 30 countries globally. It also partners with local healthcare providers, including specialized diabetes centers, to offer comprehensive training on insulin pump usage and effective diabetes management strategies.
The company currently has 4 insulin pumps in its portfolio; however, they should soon be looking for the right partners for evolving its portfolio to meet the market needs. In 2020, SOOIL entered into a collaboration with France based Diabeloop, evaluating Dana-i Diabecare Pump in combination with Diabeloop’s DBLG1 i-controller to allow the insulin pump to get FDA approval as an alternate controller enabled (ACE) insulin pump. This study was impacted by COVID pandemic and the current status is unclear.
Insulin Pumps Portfolio:
The table below presents information on insulin pumps manufactured by SOOIL Development, providing details on the stage of development, type of pump (tubed or tubeless), degree of automation, and type of dose administered (basal or bolus).
 |
Recent Developments:
October 2023: The company participated in the International Conference on Diabetes and Metabolism, held in Kyeong-Ju, Korea.
October 2023: The company participated in the EASD 2023, held in Hamburg, Germany.
June 2023: The company participated in the ADA 2023, held in Orlando, US.
May 2023: The company participated in the 36th annual meeting of the Korean Diabetes Association, held in Gwang Ju, Seoul.
February 2023: The company participated in the 16th Advanced Treatment Technology Diabetes (ATTD 2023), held in Berlin, Germany.
Further information related to the insulin pump portfolio of SOOIL Development and other insulin pump manufacturers is available in the full report.
Roche Launched mySugr Pump Control, Simplifying Accu-Chek Insight Insulin Pump Therapy Through a Smartphone; Plans for Development of Insulin Pump – CGM Combination Device
 |
Roche, a biotechnology company, is engaged in development of medicines and diagnostics for numerous medical fields, such as neurology, immunology, infectious diseases, ophthalmology and oncology. Leveraging nearly five decades of experience in diabetes management, Roche offers a range of products and services for diabetic patients through its Roche Diabetes Care division. The company's offerings include blood glucose meters, lancing devices, data management systems, and software and applications. Further, it continually aims to develop novel products that enhance the understanding of diabetes and allow personalized patient care approaches. The company also entered the diabetes drugs market with the acquisition of Carmot Therapeutics in December 2023. This acquisition provided Roche with three GLP-1 drugs in its portfolio for treatment of obesity and diabetes.
Roche plans to enter the CGM market with its first product Accu-Chek Smartguide, which received CE market approval in July 2024. The launch of this CGM, which used predictive AI technology, will set the stage for integration of CGM with their insulin pumps.
For FY2023, Roche Diabetes Care segment reported revenues of $481 million.
Insulin Pumps Portfolio:
The table below presents information on insulin pumps manufactured by Roche, providing details on the stage of development, type of pump (tubed or tubeless), degree of automation, and type of dose administered (basal or bolus).
 |
Recent Developments:
- April 2024: The company signs Memorandum of Understanding (MoU) with VinCense to augment access to diabetes care in Tamil Nadu.
- November 2023: The company participated in Diabetes Professional Care conference, held in London, UK.
- September 2023: The company participated in National Conference of the Primary Care Diabetes Society (PCDS), held in Birmingham, UK.
- April 2023: The company participated in Diabetes UK Professional Conference (DUKPC), held in Liverpool, UK.
Further information related to the insulin pump portfolio of Roche and other insulin pump manufacturers is available in the full report.
Insulet, Offers a Line of Tubeless, Wearable, Pod-Based Insulin Management System, Namely Omnipod®; Rising Demand for Omnipod 5 has Led to Manufacturing Expansion
 |
Insulet is a company engaged in developing innovative medical devices for diabetic patients. The firm’s proprietary insulin management system, namely Omnipod comprises of small, self-adhesive, tubeless device (Pod), which can be worn directly on the body; it also includes wireless companion, handheld Personal Diabetes Manager (PDM), a built-in blood glucose meter (allowing users to conveniently monitor their blood glucose levels at any given moment). Such devices, also known as patch pumps, are type of wearable injectors. Notably, the system allows for up to three days of continuous insulin delivery, without the need to see or touch a needle. According to the firm’s website, its products are available in more than 20 countries, across the globe.
For FY2023, the company reported revenues of $1.7 billion, with Omnipod 5 contributing $1 billion in sales. Keeping up with the demand for its automated insulin device, the company opened a new 400,000 square foot manufacturing facility in Malaysia.
Insulin Pumps Portfolio:
The table below presents information on insulin pumps manufactured by Insulet Corporation, providing details on the stage of development, type of pump (tubed or tubeless), degree of automation, and type of dose administered (basal or bolus).
 |
Recent Developments:
- June 2024: The company participated in Jefferies Global Healthcare Conference, held in New York City, New York.
- June 2024: The company announced the commercial launch of Omnipod 5 Automated Insulin Delivery (AID) System in the UK and Netherlands for individuals aged two years and older with type 1 diabetes
- March 2024: The company participated in The Raymond James & Associates 45th Annual Institutional Investors Conference, held in Orlando, Florida.
- March 2024: The company participated in 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), held in Florence, Italy, as well as virtually.
- August 2023: The company announced the commercial launch of Omnipod 5 Automated Insulin Delivery System in Germany in order to grow its customer base.
- June 2023: The company participated in American Diabetes Association (ADA) 83rd Scientific Sessions, held in San Diego, California.
- June 2023: The company participated in William Blair & Company 42nd Annual Growth Stock Conference, held in Chicago, Illinois.
- February 2023: The company acquired assets related to pump-based AID technologies offered by Bigfoot Biomedical for a total consideration of USD 25 million.
- February 2023: The company acquired portfolio of AID technology offered by Automated Glucose Control LLC (AGC) for a total consideration of USD 25 million
Further information related to the insulin pump portfolio of Insulet Corporation and other insulin pump manufacturers is available in the full report.
Tandem Diabetes Care, Acquired AMF Medical To Incorporate Insulin Patch Pumps in its Product Portfolio
 |
Tandem Diabetes Care is engaged in the manufacturing and sales of advanced, AID systems. The company has various insulin pumps in its product portfolio that feature the Control-IQ advanced hybrid closed-loop technology (helping in reducing glucose variability). As per the company website, its pumps are integrated platforms that combine diabetes treatment and smart technologies. Further, it provides personal pump training to new users so they can quickly learn to use the products.
In January 2023, the company acquired Switzerland based AMF Medical for a sum of $216 million. AMF Medical was developing a rechargeable insulin patch pump, Sigi, at the time of acquisition.
Insulin Pumps Portfolio:
The table below presents information on insulin pumps manufactured by Tandem Diabetes Care, providing details on the stage of development, type of pump (tubed or tubeless), degree of automation, and type of dose administered (basal or bolus).
 |
Recent Developments:
- June 2024: The company participated in American Diabetes Association’s 84th Scientific Sessions, held in Orlando, Florida.
- January 2024: The company announced the commercial launch of the world’s smallest and durable AID system, namely Tandem Mobi system, in the US
- June 2023: The company participated in Jefferies Healthcare Conference, held virtually.
- May 2023: The company participated in BofA Securities 2023 Health Care Conference, held virtually.
- January 2023: The company participated in 41st Annual J.P. Morgan Healthcare Conference, held virtually.
- January 2023: The company acquired Capillary Biomedical in order to develop new and innovative wearable infusion set solutions
Further information related to the insulin pump portfolio of Tandem Diabetes Care and other insulin pump manufacturers is available in the full report.
What About the Other Insulin Pump Manufacturers?
The above presentation features the top 5 insulin pump manufacturers selected from a pool of over 25 firms that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources:
1. “Arecor And Medtronic Diabetes Establish Collaboration To Develop A Novel Thermostable Insulin For Implantable Pump Delivery”
2. “Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands”
3. “Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System”